DENVER, Colo. (247marketnews.com) – Today’s market narratives include NeoVolta (NASDAQ:NEOV), NeOnc (NASDAQ:NTHI), Eli Lilly (NYSE:LLY), CollPlant (NASDAQ:CLGN), Boeing (NYSE:BA), and RedHill Biopharma (NASDAQ:RDHL).
NeoVolta: 18 GWh Battery Deal Puts NeoVolta in the U.S. Energy-Storage Fast Lane
NeoVolta (NASDAQ:NEOV) is making a much bigger bet on the U.S. battery-storage boom, announcing a five-year strategic supply and manufacturing collaboration with SK On that could support up to 18 gigawatt-hours of combined activity from 2027 through 2031. The signed agreement initially secures 9 GWh of U.S.-manufactured lithium iron phosphate, or LFP, battery cells for NeoVolta Power, while a broader framework calls for another 9 GWh of cells and for NeoVolta Power to manufacture energy-storage packs that SK On would purchase.
The headline number is significant because NeoVolta is trying to transform itself from a smaller energy-storage player into a domestic battery manufacturing platform. The company says the collaboration could support expansion of its Pendergrass, Georgia facility toward a two-line operation targeting as much as 8 GWh of annual BESS production capacity in 2028. CEO Ardes Johnson called the agreement “an important milestone” in NeoVolta’s expansion into large-scale energy storage and said it reinforces the company’s strategy to build a domestic platform for growing demand across commercial, industrial, utility and AI-data-center applications.
SK On's participation gives the story another dimension. Reuters reported that the South Korean battery manufacturer is increasingly targeting energy-storage systems as the EV-battery market changes, with the NeoVolta agreement providing a U.S.-based outlet for LFP cells produced at SK On’s Georgia operations. SK On executive Daejin Choi said, “This partnership strengthens SK On’s position in the U.S. BESS market,” while describing NeoVolta Power as a strategic partner for expanding the company’s U.S. energy-storage presence.
NeOnc Technologies Holdings: NEO100 Data Creates a New Regulatory Catalyst for a High-Risk Brain-Cancer Bet
NeOnc (NASDAQ:NTHI) has moved NEO100 into a potentially more consequential phase after reporting positive topline Phase 2a results in recurrent or progressive IDH1-mutant Grade III and Grade IV glioma. The company reported 48.9% six-month progression-free survival, compared with a prespecified 20% benchmark, with a reported p-value of 0.0047. Median overall survival was reported at 26.09 months, while 86.7% of patients were alive at six months.
The most important development may be what happens next. NeOnc says it intends to request a Type B meeting with the U.S. Food and Drug Administration to discuss the potential registrational pathway for NEO100. That turns the story from a pure clinical-data trade into a regulatory-development story. CEO Amir Heshmatpour said the company’s priority is to engage with the FDA and “align on the most efficient path toward a registrational study.”
NEO100 also brings a differentiated delivery angle. The drug is administered intranasally, potentially offering a way to deliver therapy to the central nervous system while avoiding conventional intravenous administration. NeOnc reported no major toxicities in the Phase 2a cohort, with adverse events predominantly low-grade, and said five of 24 patients remained on treatment at the time of the update. One patient reportedly had an ongoing partial response beyond 114 days.
The bullish narrative is obvious: a small biotechnology company has produced a clinically meaningful signal in a difficult cancer setting and now has an identifiable regulatory catalyst.
Eli Lilly: $2.88 Billion Merida Deal Signals Lilly is Hunting Beyond Obesity
Eli Lilly (NYSE:LLY) is using the enormous commercial success of its obesity and diabetes franchise to push aggressively into the next generation of medicines. The latest move is an agreement to acquire privately held Merida Biosciences for up to $2.875 billion in cash, bringing Merida’s experimental autoimmune-disease platform into Lilly’s immunology pipeline. The transaction includes an upfront payment plus milestone-based consideration and is expected to close in the fourth quarter of 2026.
Merida’s lead program, MER511, is an early-stage therapy aimed at diseases including Graves’ disease and thyroid eye disease. Rather than broadly suppressing the immune system, Merida is developing what Lilly describes as a precision approach intended to selectively target disease-driving antibodies. Lilly said early clinical data showed substantial reductions in thyroid-stimulating antibodies alongside a favorable initial safety profile.
The strategic appeal is that Lilly is buying optionality in a market where disease-modifying approaches could command substantial value if clinical development succeeds. Francisco Ramírez-Valle, Lilly’s senior vice president of immunology research and early clinical development, said, “We're building our pipeline around therapies that meaningfully change the course of disease, not just its downstream effects.” He added that Merida’s lead program is designed to do exactly that.
Lilly’s acquisition spree also highlights a broader pharmaceutical-industry trend: blockbuster cash flows are being recycled into pipeline assets before competitors can establish themselves in emerging therapeutic categories. Merida’s pipeline extends beyond MER511, including MER769 for food allergy, asthma and other allergic diseases.
CollPlant Biotechnologies: Tiny Biotech Makes a Radical Pivot into Photonic Supercomputing
CollPlant (NASDAQ:CLGN) is attempting one of the more dramatic corporate pivots in the small-cap market, signing a definitive agreement to acquire Israeli deep-tech company LightSolver and enter the photonic-computing and high-performance-computing markets. The transaction is expected to close this week and would give CollPlant control of LightSolver’s Laser Processing Unit, or LPU, an all-optical computing architecture designed to use lasers rather than conventional electronic processing as the computational medium.
LightSolver is positioning its LPU as a new computing layer alongside CPUs and GPUs, targeting workloads involving scientific simulation, optimization, engineering, large-scale linear systems and Physical AI. The company says its technology is designed to operate at room temperature without the cryogenic requirements associated with many quantum-computing systems. Commercial validation is reportedly underway with organizations in aerospace, defense, finance, energy and engineering software.
The Boeing connection adds serious commercial intrigue. LightSolver has announced a funded financial and engineering partnership with Boeing (NYSE:BA) focused on applying the LPU to complex aerospace simulations. The technology is being aimed at problems such as structural degradation, lifecycle prediction and computationally intensive engineering workloads. LightSolver founder and CEO Dr. Ruti Ben Shlomi described the broader vision bluntly: “Computing is reaching an inflection point,” arguing that the next major leap could come from changing the medium of computation “from electrons to light.”
But CLGN investors are also getting a major transaction-structure story. CollPlant plans to issue 3,734,476 ordinary shares, representing 19.7% of its pre-transaction shares, plus pre-funded warrants for 6,134,363 shares and milestone warrants covering up to 224,078,345 additional shares. Some issuances are subject to shareholder approval because of Nasdaq listing requirements. That creates potentially enormous upside optionality if LightSolver succeeds—but also substantial potential dilution.
CollPlant CEO Yehiel Tal called the transaction “transformational” and said it opens “an extraordinary new growth vector” in photonic computing while maintaining a commitment to the company’s regenerative-medicine and medical-aesthetics activities. The challenge is equally extraordinary: CLGN is moving from biotechnology into a highly competitive computing landscape where commercialization is still targeted for 2028. If LightSolver delivers, the deal could completely change the market’s perception of CollPlant; if it does not, the transaction’s equity-heavy structure could become a major overhang.
RedHill Biopharma: $18 Million Talicia Cash-Out Gives RedHill a Fresh Shot at Its GI Comeback
RedHill Biopharma (NASDAQ:RDHL) is selling the asset that helped define its U.S. commercial identity, divesting its remaining 70% interest in Talicia to an Apotex Health Corp. subsidiary for $18 million upfront, plus up to $35 million in potential worldwide net-sales milestones. The transaction consolidates Talicia under Apotex after the company previously acquired Cumberland Pharmaceuticals' 30% interest in the business.
For RedHill, the deal is less about abandoning gastrointestinal medicine than about freeing capital from a complicated ownership structure. The company says the transaction immediately strengthens liquidity and is intended to fund a larger commercial expansion centered on new FDA-approved products. CEO Dror Ben-Asher called it “a pivotal milestone for RedHill,” saying the company is converting its 70% Talicia stake into “immediate capital, significantly stronger liquidity and meaningful potential upside.”
Talicia is an FDA-approved rifabutin-based combination therapy for H. pylori infection, a bacterial infection associated with peptic ulcers and gastric cancer. With Apotex now acquiring full ownership, RedHill gets cash today while retaining potential milestone economics if worldwide Talicia sales hit specified targets. The SEC filing confirms the $18 million upfront payment and up to $35 million in additional milestone payments, along with a five-year U.S. non-compete covenant covering competing products.
That leaves investors with a very straightforward test of management’s strategy: can RedHill turn the proceeds into a larger, more valuable GI franchise? Management says the cash will support “new, high-value, FDA-approved product opportunities” and help accelerate the company toward operational profitability. RedHill still has development programs including opaganib, RHB-102, RHB-204 and RHB-107, but the burden now shifts toward execution. The Talicia monetization creates liquidity; the next question is whether management can convert that liquidity into sustainable revenue growth.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
